Pharming Group NV
AEX:PHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharming Group NV
AEX:PHARM
|
NL |
|
Companhia de Saneamento Basico do Estado de Sao Paulo SABESP
F:SAJA
|
BR |
|
Daito Trust Construction Co Ltd
OTC:DIFTY
|
JP |
|
W
|
WD-40 Co
F:WD1
|
US |
|
F
|
Fomento de Construcciones y Contratas SA
DUS:FCC
|
ES |
|
Mitsui E&S Holdings Co Ltd
TSE:7003
|
JP |
|
A
|
Alpha Pro Tech Ltd
AMEX:APT
|
CA |
Wall St Price Targets
PHARM Price Targets Summary
Pharming Group NV
According to Wall Street analysts, the average 1-year price target for PHARM is 2.2568 EUR with a low forecast of 1.818 EUR and a high forecast of 2.73 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PHARM's stock price target?
Price Target
2.2568
EUR
According to Wall Street analysts, the average 1-year price target for PHARM is 2.2568 EUR with a low forecast of 1.818 EUR and a high forecast of 2.73 EUR.
What is the Revenue forecast for Pharming Group NV?
Projected CAGR
20%
Over the last 14 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 5 years is 20%.
What is the Gross Profit forecast for Pharming Group NV?
Projected CAGR
0%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 49%. The projected CAGR for the next 3 years is 0%.
What is the Operating Income forecast for Pharming Group NV?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 5 years is 36%.
What is the Pre-Tax Income forecast for Pharming Group NV?
Projected CAGR
53%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 53%.
What is the Net Income forecast for Pharming Group NV?
Projected CAGR
112%
The compound annual growth rate for Net Income over the next 5 years is 112%.
